Clinical Trial Update: Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2 [Phase 2]

View source ↗

Summary

Phase II trial update of a B7-1 gene-modified autologous tumor cell vaccine with systemic IL-2 in renal cell carcinoma; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• B7-1 gene-modified autologous tumor cell vaccine
• Interleukin-2 (IL-2) (interleukin-2)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED